McKesson Corporation (MCK) Presents at UBS Global Healthcare Conference 2025 Transcript

Core Insights - The North American Pharmaceutical business has shown stronger-than-expected margins when separated from the Specialty business, indicating underlying improvements in the sector [1] Group 1: Business Performance - The North American Pharma margins, excluding Oncology and Specialty, were stronger than anticipated, suggesting positive changes in the business dynamics [1] - The integration of Canada into the North American Pharma segment may have contributed to the improved performance [1] Group 2: Market Dynamics - The ongoing tracking of generic pricing and mix indicates that these factors have remained stable, yet other elements within the business are driving improvements [1]